A detailed history of First Horizon Advisors, Inc. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 282 shares of SRPT stock, worth $37,601. This represents 0.0% of its overall portfolio holdings.

Number of Shares
282
Previous 289 2.42%
Holding current value
$37,601
Previous $45,000 22.22%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$124.33 - $156.75 $870 - $1,097
-7 Reduced 2.42%
282 $35,000
Q2 2024

Jul 19, 2024

BUY
$113.33 - $163.85 $2,379 - $3,440
21 Added 7.84%
289 $45,000
Q4 2023

Feb 06, 2024

BUY
$67.31 - $124.76 $1,346 - $2,495
20 Added 8.06%
268 $25,000
Q3 2023

Oct 27, 2023

BUY
$102.5 - $123.59 $307 - $370
3 Added 1.22%
248 $30,000
Q2 2023

Aug 03, 2023

BUY
$106.4 - $157.19 $19,684 - $29,080
185 Added 308.33%
245 $28,000
Q1 2023

May 15, 2023

BUY
$117.53 - $155.99 $3,055 - $4,055
26 Added 76.47%
60 $8,000
Q2 2022

Aug 02, 2022

BUY
$62.69 - $88.44 $2,131 - $3,006
34 New
34 $2,000
Q1 2022

May 10, 2022

SELL
$63.15 - $90.42 $2,147 - $3,074
-34 Closed
0 $0
Q4 2021

Feb 09, 2022

SELL
$77.28 - $99.42 $540 - $695
-7 Reduced 17.07%
34 $3,000
Q3 2021

Nov 15, 2021

SELL
$65.97 - $92.48 $4,749 - $6,658
-72 Reduced 63.72%
41 $3,000
Q3 2021

Nov 09, 2021

BUY
$65.97 - $92.48 $4,947 - $6,936
75 Added 197.37%
113 $10,000
Q1 2021

May 11, 2021

BUY
$72.25 - $168.95 $216 - $506
3 Added 8.57%
38 $2,000
Q4 2020

Feb 11, 2021

BUY
$125.56 - $178.74 $1,757 - $2,502
14 Added 66.67%
35 $5,000
Q3 2020

Nov 12, 2020

BUY
$127.12 - $172.34 $254 - $344
2 Added 10.53%
21 $2,000
Q1 2020

May 05, 2020

BUY
$82.38 - $131.64 $1,565 - $2,501
19 New
19 $1,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $11.7B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.